Article info
PDFResearch ethics
Paper
The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries
- Correspondence to Dr Christine Grady, Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA; cgrady{at}cc.nih.gov
Citation
The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries
Publication history
- Received August 15, 2011
- Revised November 1, 2011
- Accepted December 14, 2011
- First published February 7, 2012.
Online issue publication
May 22, 2012
Article Versions
- Previous version (7 February 2012).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- The standard of care debate: the Declaration of Helsinki versus the international consensus opinion
- Is it ethical to deny genetic research participants individualised results
- Cultural considerations for informed consent in paediatric research in low / middle - income countries: a scoping review
- Between universalism and relativism: a conceptual exploration of problems in formulating and applying international biomedical ethical guidelines
- The battering of informed consent
- Double Standards in Medical Research in Developing Countries
- To stop or not to stop: dissent and undue burden as reasons to stop participation in paediatric research
- Regulation of biomedical research in Africa
- Ethical issues raised by cluster randomised trials conducted in low - resource settings: identifying gaps in the Ottawa Statement through an analysis of the PURE Malawi trial
- Eliminating the daily life risks standard from the definition of minimal risk